Triamcinolone joint injection, Dr.Conaghan #RNL2023 ⁦@RheumNow⁩ Extended half life steroids injections are better?!: 1- better for sugar control. 2-longer effect. https://t.co/4T8frPJOXG

#RNL2023 @RheumNow @DrLauraCoates: patients & physicians do not agree on what is remission in PsA Patients global scores: largely driven by pain and fatigue, not on joint counts Remission in PsA allows for disease control on Rx- not just drug-free remission, often not sustained https://t.co/Hr2uuWDAfr

Higher Rehospitalization Rates in Younger SLE Patients A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients. https://t.co/17Lbcw8TdC https://t.co/L6CwRCd1aS

• https://bit.ly/3JQNOyV

Can we prevent RA, Kevin Deane #RNL2023 ⁦@RheumNow⁩. https://t.co/EtUEs3MyCN

Upto 30% risk of #RA within 5 yrs if anti-CCP positive #RNL23 https://t.co/E5wun837ud

Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated? Can there be sustained response. Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪 @RheumNow https://t.co/eBMEPBG9wn

Stop RA trail: Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/2Y5am2YEsQ

Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA @RheumNow https://t.co/Ieagp8mq31

30% rule! Risk of RA development in Pre clinical RA patient in the next 3 to 5 years . Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/J6Polz70im

Dr Philip Conaghan at #RNL2023 X-rays are misleading in OA OA is a CLINICAL disease Radiographs do not help in diagnosis or monitoring ⁦@RheumNow⁩ https://t.co/ZrAfPN02qi

#RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/zJRRisGW9i

@RheumNow Live #RNL2023 Stanley Cohen, MD: Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16 ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG

Dr Brenner at #RNL2023 Excellent description on how fibroblasts are major producers of IL-6 producers Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA @RheumNow https://t.co/TserFZtvhV

JAKinib safety takeaways - avoid in older population > 65 yo, malignancy, CV risk, VTE risk - appropriate in younger pts without VTE/CVD risk factors #RNL2023 @RheumNow https://t.co/5i1bRqqr7g

@RheumNow Live 2023 Starts Tomorrow! Or does it start earlier? Love that there is a pre-learn and pre-test to set the stage for #RNL2023 Excited for this talk by @anisha_dua on assessment for GCA/PMR #RheumTwitter https://t.co/VcawlnaPFf